TrialHead & neck2020

Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.

Janneke C Ham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.